Editas Medicine, Inc. reported Q4 and full year 2025 financial results with net loss of $5.6 million ($0.06 per share) for Q4 and $160.1 million ($1.80 per share) for the year, improved from prior year, alongside cash of $146.6 million funding into Q3 2027. Lead candidate EDIT-401 remains on track for IND/CTA submission by mid-2026 and first-in-human trial in HeFH patients with proof-of-concept data by year-end 2026.
Key takeaways
Cash and cash equivalents $146.6 million as of Dec 31, 2025, runway into Q3 2027
Q4 2025 net loss $5.6 million or $0.06 per share vs $45.4 million or $0.55 per share in Q4 2024
Full year 2025 net loss $160.1 million or $1.80 per share vs $237.1 million or $2.88 per share in 2024
EDIT-401 demonstrated >90% mean LDL-C reduction in preclinical studies in non-human primates
On track for EDIT-401 IND/CTA submission by mid-2026 and first-in-human HeFH trial later 2026
R&D expenses decreased $21.2 million to $27.4 million in Q4 2025 due to reni-cel discontinuation